Bayer Schering Pharma Strengthens Position in Specialty Care www.kompas.com, 2007-04-09
After the 17-billion Euro acquisition of Schering Indonesia by Bayer Indonesia, the merged company aims to target the specialty care market. Bayer Schering Pharma Indonesia, a division of Bayer Indonesia, has made an investment of 1.4 billion Euro for research and development. In time, there will be 22 brands of medicine marketed using the Bayer Schering brand, which include Adalat OROS®, Avelox® , Cardio Aspirin® , Glucobay® , Ciproxin XR® , Levitra® , Nebido® , Incidal-OD® , Yasmin® , Diane 35® , Microgynon® , Primolut N® , Angeliq® , Mirena® , Nexavar® , Ventasis® , Betaferon® , Bonefos® , Fludara® , Androcur® , Magnevist® and Ultravist®.
Bayer’s Pesticide Market Increases Slightly by 7 Percent Bisnis Indonesia, page T7, 2005-07-20
Bayer CropScience, a sub-division of PT Bayer Indonesia, underwent domestic market segment increase of 7 percent for the pesticide market for the first semester of 2005. The not so significant growth is due to the specific nature of the industry. Demands from domestic industries are relatively flat and do not grow as fast as other industries. This is related to volume export that is not as abundant as other countries. Stable growth in this field can be acquired due to good climate, stable political condition and supportive government policies.
Copyright & Disclaimer PT. Dataindo Inti Swakarsa makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the features, functions, tools, data or information contained herein.Information provided is not financial product advice. This report contains general information only. It is not intended as financial product advice and must not be relied upon as such. You should consider obtaining independent advice tailored to your specific circumstances before making any financial decisions. Copyright in this publication is owned by PT. Dataindo Inti Swakarsa. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication - in papers, reports, or opinions prepared for any other person - it is agreed that it will be sourced to: PT. Dataindo Inti Swakarsa